Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Agilent Technologies is a leading life sciences, diagnostics, and applied chemical markets instrumentation company serving pharmaceutical, biotech, clinical/diagnostic labs, and chemical/energy customers globally. The company provides analytical instruments (LC/MS, GC/MS, spectroscopy), consumables (columns, reagents), and software/services for drug discovery, quality control, food safety, and environmental testing. Competitive advantages include installed base of ~1 million instruments generating recurring consumables/service revenue, leading market positions in liquid chromatography and mass spectrometry, and sticky customer relationships in regulated industries.
Agilent operates a razor-razorblades model: selling high-value capital equipment ($50K-$500K+ per instrument) creates an installed base that generates recurring revenue from consumables (columns, reagents with 40-60% gross margins), service contracts (15-20% of instrument value annually), and software subscriptions. Pharma and biotech customers represent ~40% of revenue with high switching costs due to validated methods in regulated environments. The company benefits from secular growth in biopharma R&D spending, increasing regulatory requirements for food/environmental testing, and shift toward precision medicine requiring advanced analytical tools. Pricing power stems from proprietary technologies (Ultivo triple quadrupole LC/MS, InfinityLab LC systems) and mission-critical nature of products in quality control workflows.
Pharma/biotech R&D spending trends and drug approval pipelines driving instrument demand
China market performance (20%+ of revenue) - government lab funding, food safety initiatives, environmental regulations
Consumables and services recurring revenue growth rates (indicates installed base health and utilization)
Operating margin expansion trajectory and ability to offset instrument pricing pressure with mix shift to higher-margin consumables
M&A activity in life sciences tools space (consolidation premium, competitive threats)
Technological disruption from lower-cost analytical platforms (miniaturized mass spec, microfluidics) or software-based alternatives reducing instrument demand
Shift toward outsourced testing (CROs, CDMOs) concentrating purchasing power and pressuring instrument pricing
China localization policies favoring domestic instrument manufacturers (Shimadzu, local players) in government-funded labs
Intense competition from Thermo Fisher Scientific (larger scale, broader portfolio), Danaher (Sciex mass spec, integrated workflows), Waters Corporation (LC specialist), and Shimadzu in core LC/MS markets
Pricing pressure in mature instrument categories (GC, basic LC) from low-cost Asian manufacturers
Customer consolidation (pharma mergers, hospital system integration) reducing number of decision-makers and increasing price sensitivity
Modest leverage at 0.50x debt/equity provides flexibility, but $1.8B debt load requires ~$60-70M annual interest expense
Pension obligations and retiree healthcare liabilities from legacy HP spinoff history, though well-funded currently
moderate - Pharma/biotech R&D spending (40% of revenue) is relatively resilient through cycles as drug development timelines span years, but chemical/energy and academic research customers (30% combined) are more cyclical. Clinical diagnostics (20%) is non-cyclical. China exposure creates sensitivity to regional economic conditions and government lab funding cycles. Instrument purchases are deferrable capex, creating 2-4 quarter lag in downturns.
Rising rates have modest negative impact through two channels: (1) biotech funding environment - higher rates reduce venture capital availability and IPO activity, pressuring smaller biotech customers' instrument budgets, and (2) valuation multiple compression for high-quality growth stocks trading at 20x+ EBITDA. However, Agilent's balance sheet is minimally affected (0.50x debt/equity, mostly fixed-rate debt). Customer financing programs for instruments see slightly lower demand when rates rise.
Minimal direct exposure. Customer base is primarily investment-grade pharma companies, government-funded labs, and established diagnostics providers. Biotech customer concentration (~15-20% of revenue) creates modest risk if venture funding dries up, but most customers are late-stage with revenue. Agilent extends limited vendor financing, primarily through third-party leasing arrangements.
growth-at-a-reasonable-price (GARP) - Investors seek consistent mid-single-digit organic growth, 20%+ operating margins, strong FCF generation ($1.2B annually), and modest capital returns (2% dividend yield, opportunistic buybacks). Appeals to healthcare/life sciences specialists valuing recurring revenue models and exposure to biopharma innovation trends. Less attractive to pure growth investors due to mature instrument markets and moderate growth rates, or deep value investors given 20x+ EBITDA valuation.
moderate - Beta typically 0.9-1.1. Stock experiences 15-25% drawdowns during broad market corrections or biotech funding cycles. Recent 14% three-month decline reflects concerns about China exposure and biotech funding environment. Less volatile than pure-play diagnostics or biotech, more volatile than diversified healthcare due to capital equipment cyclicality.
